Preview: Mind Medicine’s Earnings

Mind Medicine (NASDAQ:MNMD) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors…

Mind Medicine (NASDAQ:MNMD) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors need to know before the announcement.

Analysts estimate that Mind Medicine will report an earnings per share (EPS) of $-0.67.

Mind Medicine bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.22, which was followed by a 7.64% drop in the share price the next day.

Here’s a look at Mind Medicine’s past performance and the resulting price change:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.54 -0.39 -0.50 -0.60
EPS Actual -0.76 -0.65 -0.02 -0.56
Price Change % -7.64% -5.8% -5.35% 11.15%

eps graph

Stock Performance

Shares of Mind Medicine were trading at $2.56 as of October 31. Over the last 52-week period, shares are down 14.59%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Mind Medicine visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Drive-Thru Cannabis Sales Help C21: Same-Store Sales Up, But Revenue Down In Q3

C21 Investments reported a 4.5% year-over-year and a 3.9% sequential decrease in revenue to $6.9 million for the third quarter ended October 31. The Vancouver-based company also reported a sequential increase in same-store sales. Gross profit totaled $2.7 million, down from $3.9 million in the prior year's quarter, and the net loss was $376,150 compared to net income of $248,507 in the same period last year. C21 Investments generated $0.9 million of adjusted EBITDA, unchanged from the prior quarter, and cash at the end of Q3 was $1.9 million, unchanged since the start of the year.

CSE:CXXI